#ASCO20 Worth reviewing this presentation by @MLJohnsonMD2 on the phase II CITYSCAPE data of atezolizumab +/- tiragolumab. Tiragolumab is an anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) molecule that prevents inhibition of T-cell and NK-cell activation. #OncoAlert
#ASCO20 Preclinical combinations show synergy with anti-PDL1 and anti-TIGIT. Full Phase I data will be at #AACR20. CITYSCAPE is a randomized phase II of 1L atezolizumab + tiragolumab/placebo in PDL1+ NSCLC. #OncoAlert #LCSM
#ASCO20 Randomized 135 patients, 43% PDL1 high. Tiragolumab improved RR (37% vs 21%). In PDL1 TPS 50%+, RR 66% vs 24% (in PDL1 low, RR 16% vs 18%). Median f/u only 10.9m so need more time but the control arm does appear a bit worse than we would expect. #OncoAlert #LCSM
#ASCO20 Tiragolumab improved PFS (HR 0.58) when added to atezolizumab, particularly in the PDL1 high subset (PFS HR 0.30!) Similar safety (withdrawal due to AE 10% vs 9%) despite doubling of treatment duration with tiragolumab. #OncoAlert #LCSM
#ASCO20 Overall, I find these compelling. In PDL1 high, RR 66% (vs 24%) and PFS HR of 0.30 when added to atezo. TIGIT expression tracks with PD-1 in tumor infiltrating T-lymphocytes. SKYSCRAPER-01 is a phase III trial exploring atezo/tira in PDL1 high NSCLC. #OncoAlert
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.